[New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)].
By Hirokazu Watanabe, M. Okada, Yasushi Kaji, M. Satouchi, Yozo Sato, Y. Yamabe, H. Onaya, M. Endo, M. Sone, Y. Arai. Gan to kagaku ryoho. Cancer & chemotherapy, 2009
2,216 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/b7406a2f2abf9aefdaf632864d5075301223d02f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- R. Scolyer
- Masatoshi Kudo
- Joong-Won Park
- S. Qin
- A. Cheng
- J. Wilmott
- Richard S. Finn
- Georgina V. Long
Citations in the corpus
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer (2019, unknown): “Vomiting 18 (20) 1 (1) 9 (15) 1 (2) 5 (−9 to 17) −1 (−8 to 5)”
- Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer (2022, unknown): “…irinotecan, and pembrolizumab); were aged 18 years or older; had adequate haematologic, renal, and liver function; had Eastern Cooperative Oncology Group performance status of 0 or 1; and had measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST, version 1.1) 40 .”
- First-line crizotinib versus chemotherapy in ALK-positive lung cancer. (2014, unknown): “Stomatitis§ 24 (14) 1 (1) 34 (20) 2 (1)”
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma (2011, background): “0 for GSK2118436 and RECIST 1 1 for vemurafenib (15, 16).”
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. (2018, methodology): “The investigators evaluated tumours in each treatment arm in accordance with mRECIST.(20,25) The liver 170 was examined with computed tomography or magnetic resonance imaging using a triphasic scanning 171 technique.”
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. (2017, unknown): “soft tissue lesion using the Response Evaluation Criteria in Solid Tumours [8,25]”